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Abstract
Hutchinson-Gilford Progeria Syndrome (HGPS) is a rare premature aging disorder caused by a de novo heterozygous point
mutation G608G (GGC.GGT) within exon 11 of LMNA gene encoding A-type nuclear lamins. This mutation elicits an internal
deletion of 50 amino acids in the carboxyl-terminus of prelamin A. The truncated protein, progerin, retains a farnesylated
cysteine at its carboxyl terminus, a modification involved in HGPS pathogenesis. Inhibition of protein farnesylation has been
shown to improve abnormal nuclear morphology and phenotype in cellular and animal models of HGPS. We analyzed
global gene expression changes in fibroblasts from human subjects with HGPS and found that a lamin A-Rb signaling
network is a major defective regulatory axis. Treatment of fibroblasts with a protein farnesyltransferase inhibitor reversed
the gene expression defects. Our study identifies Rb as a key factor in HGPS pathogenesis and suggests that its modulation
could ameliorate premature aging and possibly complications of physiological aging.
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Introduction
Hutchinson–Gilford progeria syndrome (HGPS) is a rare,
sporadic genetic disorder with phenotypic features of premature
aging [1][2,3,4]. It is caused by de novo dominant mutations in
LMNA [5,6,7]. LMNA encodes A-type nuclear lamins, with the
predominant somatic cell isoforms lamin A and lamin C arising by
alternative RNA splicing [8]. Lamins are intermediate filament
proteins that polymerize to form the nuclear lamina, a meshwork
associated with the inner nuclear membrane. HGPS is one of a
spectrum of diverse diseases, sometimes referred to as ‘‘lamino-
pathies,’’ caused by mutations in LMNA [9].
Lamin A is synthesized as a precursor, prelamin A, which has a
CaaX motif at its carboxyl terminus. The CaaX motif signals a series
of catalytic reactions resulting in a carboxyl-terminal cysteine that is
farnesylated and carboxymethylated [9]. Farnesylated, carboxy-
methylated prelamin A is normally cleaved near its carboxyl-terminus
in a reaction catalyzed by ZMPSTE24 endoprotease, leading to
removal of the farnesylated cysteine [9]. The LMNA G608G
mutation responsible for the majority of cases of HGPS creates
an abnormal splice donor site within exon 11, generating an mRNA
that encodes a prelamin A with a 50 amino acid deletion at its
carboxyl-terminal domain [5,6]. The ZMPSTE24 endoproteolytic
site is deleted from progerin and hence retains a farnesylated and
carboxymethylated cysteine at its carboxyl terminus [9]. Expression
of progerin induces severe abnormalities in nuclear morphology,
heterochromatin organization, mitosis, DNA replication and DNA
repair [5,6,10,11,12,13,14,15]. Progerin toxicity is attributed at least
in part to its farnesyl moiety, as chemical inhibitors of protein
farnesyltransferase (FTIs) reverse abnormalities in nuclear morphol-
ogy in progerin expressing cells [16,17,18,19,20]. In addition, FTIs
and other chemical inhibitors of protein prenylation partially reverse
progeria-like phenotypes in genetically modified mice that express
progerin or lack ZMPSTE24, and therefore accumulate unprocessed,
farnesylated prelamin A [21,22,23,24].
While several studies have clearly implicated farnesylated
progerin in HGPS, the precise molecular mechanisms of how it
induces HGPS pathology remain to be understood. Initial gene
expression profiling of fibroblasts from human subjects with
progeria syndromes and transfected cell models identified
changes in sets of genes implicated in diverse pathways that
have not always been consistent and have not been shown to
be reversed by interventions such as treatment with FTIs
[25,26,27,28]. Therefore, we carried out additional genome-wide
expression studies in cells from children with HGPS to identify
alterations in functional groups of genes that define defective
signaling pathways and to determine if FTI treatment reverses
these defects. Our results demonstrate a link between progerin
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and the retinoblastoma protein (Rb) signaling pathway in
HGPS.
Results
Lamin A-Rb signaling network is implicated in HGPS
pathophysiology
To determine the mechanisms by which progerin exerts its
pathological effect, we performed parallel microarray analyses of
fibroblasts from subjects with HGPS and control individuals that
were treated or untreated with the FTI lonafarnib for three days.
We used RNA isolated from fibroblasts from five subjects with
HGPS and five unaffected individuals to hybridize Affymetrix
U133 plus 2.0 arrays. We identified 50,636 probe sets (Fig. 1A)
and analyzed the data as described in Materials and Methods.
We first focused on the different gene expression profiles in
fibroblasts from controls and subjects with HGPS that were not
treated with FTI. We found that 352 genes were significantly
differentially expressed between fibroblasts from subjects with
HGPS and controls. Of those genes, 306 were downregulated and
46 upregulated in fibroblasts from subjects with HGPS. The
assigned subcellular localizations indicated that at least 31.6% of
the gene products were localized to the nucleus, 30.4% to the
cytoplasm, 23.7% to the plasma membrane and 1.8% to the
extracellular matrix, with the remainder unknown (Fig. 1B).
Molecular function analyses (Fig. 1C) and physiological distribu-
tions (Fig. 1D) indicated that a significant number of genes were
implicated in lipid metabolism, cell growth and differentiation, cell
cycle, DNA replication and repair as well as cardiovascular system
development.
Of the 352 genes differentially expressed in cells from subjects
with HGPS, 280 genes had known interactions according to
MetaCore database (www.genego.com). To build networks
integrating these genes, we added LMNA because, although its
levels of expression remained unchanged, mutations in this gene,
which result in abnormal protein expression, are the cause of
HGPS (Fig. 2). Of the genes with altered expression in HGPS, the
MetaCore method identified Rb1 as the only one encoding a
protein product, Rb, known to interact directly with A-type lamins
[29,30]. The expression of Rb1 was downregulated in HGPS.
Based on differential expression of other genes and known direct
protein interactions and relationships, the MetaCore analysis
identified additional downstream factors in a signaling network
that were altered in cells from subjects with HGPS (Fig. 2). This
signaling network started with lamin A/C (layer 1), which is
altered by the LMNA mutation leading to progerin expression, and
impacted Rb (layer 2). The most direct downstream targets of Rb1
were p107, NCOA2, SP1 and ATF2 (layer 3). We added E2F1 to
this network, a direct Rb interacting partner although its
expression level was not changed. These five factors then had
downstream direct effects on 15 other transcription regulators
(layer 4). Of these 15 genes, the expression levels of 13 were
significantly downregulated in fibroblasts from subjects with
HGPS with the exception of ANCO-1, which was upregulated.
HNF4-alpha and c-Myc were added to the network even though
their levels remained unchanged to allow the integration of the
remaining downstream target genes. In the next downstream layer
(layer 5), more nuclear factors were connected and all these genes
had significantly lower levels of expression in fibroblasts from
subjects with HGPS. From the 15 nuclear factors in layer 4, the
network divided into several sub-networks, which included the
JAK pathway implicated in the regulation of cell proliferation,
differentiation and survival, a group of genes related to motility
and cytoskeletal organization, and another group of genes
implicated in DNA replication and repair (Fig. 2, and Figures
S1, S2, S3, S4).
The differential expression of most of the identified genes in
HGPS can potentially be explained by the hypothesis that an
abnormal prelamin A variant causes Rb to differentially interact
with or regulate downstream partners. Most of these genes have at
least one direct connection to an upstream nuclear factor (Fig. 2,
right panel). Importantly, the differentially expressed genes in
HGPS indicated that Rb is a key regulatory component affected
by LMNA mutation and that it is at the center of a signaling
network that is abnormally active in the disease.
The lamin A-Rb signaling network is modulated by FTI
treatment
To unravel the mechanism underlying reversal of the HGPS
phenotype by blocking protein farnesylation, we determined the
gene expression changes occurring in fibroblasts after FTI
administration. Fibroblasts from normal subjects and subjects
with HGPS were grown in medium supplemented daily with
1.5 mM of lonafarnib for three days. Trypan blue exclusion assays
indicated that less than 2% of cells died whether or not they were
treated with FTI (data not shown). We monitored the inhibition of
protein farnesyltransferase by screening for unprocessed HDJ-2
and prelamin A. FTI-treated control cells exhibited an average of
64.0%60.7 (mean 6 SD., n= 3, P,0.05) non-farnesylated HDJ-2
and accumulation of prelamin A (Fig. 3A). FTI-treated fibroblasts
from subjects with HGPS exhibited 62.3%61.5 (n = 3, P,0.05)
non-farnesylated HDJ-2 with a similar increase in prelamin A
(Fig. 3A), indicating that protein farnesyltransferase activity was
similarly inhibited in cells from control individuals and those
with HGPS.
We first examined the effects of FTI treatment on normal
fibroblasts by using Ingenuity Pathways Analysis (IPA) to compare
gene expression profiles in fibroblasts from control individuals with
or without FTI treatment. This analysis identified significant
differences in the expression of 65 genes, with 47 downregulated
and 18 upregulated in cells treated FTI. The majority of these
genes were functionally assigned to cell cycle, DNA replication and
repair and purine and pyrimidine metabolism; 63% of the
encoded proteins were nuclear (Figure S5).
The 65 differentially expressed genes were assembled into a
network based on known protein interactions in the MetaCore
database. The changes in FTI-treated control cells can be
explained by a direct effect of inhibition of protein farnesyltrans-
ferase (Fig. 3B). Inhibition of protein farnesyltransferase would
subsequently affect three of its substrates, centromeric proteins F
and E (CENP-F and CENP-E), the genes of which had altered
expression in FTI-treated cells, and lamin A/C. Even though
lamin A/C levels remained unchanged it was added to the
network because FTIs induce the accumulation of unfarnesylated,
unprocessed prelamin A. CENP-E interacts with TPX2 and
CENP-F interacts directly with Rb. These proteins therefore were
added to the network even though their levels remained
unchanged in FTI-treated cells. Rb directly interacts with lamin
A/C and with E2F1, repressing its transcriptional activity.
Expression of all of the downstream targets of E2F1 was
downregulated in the FTI-treated cells (Fig. 3B). These results
indicate that FTI treatment affects a sequential cascade of events
starting from inhibition of protein farnesyltranferase, which in turn
modifies centromeric proteins and lamin A/C and possibly their
interactions with Rb. Alterations in Rb function in turn influence
the activity of the transcription factor E2F1, a key regulator of
downstream genes with decreased expression in fibroblasts after
FTI treatment.
Defective Rb Signaling in HGPS
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FTI restores a nearly normal gene expression profile in
fibroblasts from subjects with HGPS
To determine the effects of a FTI on gene expression in cells
from subjects with HGPS, we generated a Venn diagram to
demonstrate overlapping alterations in expression in three datasets
(Fig. 4A). The three datasets were: (1) genes differentially expressed
in fibroblasts from controls subjects after FTI treatment compared
to no treatment (65 genes); (2) genes differentially expressed in
fibroblasts from subjects with HGPS compared to those from
control subjects (352 genes); and (3) genes differentially expressed
in fibroblasts from subjects with HGPS after FTI treatment
compared to those from untreated control subjects (804 genes).
Differential expression of 25 genes were specific to FTI-treated
control fibroblasts (dataset 1); 40 genes were commonly differen-
tially expressed in these cells as well as in cells from subjects with
HGPS treated with FTI (dataset 1 compared to dataset 2). Only
one gene, SMC2, a structural maintenance factor of chromosome 2
was common between the three datasets.
We focused on the gene expression profile resulting from FTI
treatment of fibroblasts from subjects with HGPS (dataset 3),
which indicated changes in the expression of 804 genes after FTI
treatment. Of these 804 genes, 414 were upregulated and 390
were downregulated. This high number of genes with altered
expression suggests that cells from subjects with HGPS were highly
sensitive to FTI. For the gene products, 31.9% were predicted to
be nuclear proteins (Fig. 4B), whereas in normal fibroblasts treated
with FTI 63% of the differentially expressed genes were predicted
to encode nuclear proteins (Figure S5). Of these 804 genes
showing differential expression after FTI treatment of cells from
subjects with HGPS, 64 were differentially expressed in untreated
cells from subjects with HGPS compared to normal fibroblasts.
Expression of the remaining 701 differentially expressed genes
were uniquely altered in FTI-treated fibroblasts from subjects with
HGPS and were functionally associated with gene expression, cell
cycle, cell growth, DNA replication and repair, molecular
transport and protein trafficking (Fig. 4C). They also were
involved in several canonical pathways involved in PI3K/AKT
signaling, protein ubiquitination and regulation of the actin
cytoskeletal network (Fig. 4D).
Only 64 genes were differentially expressed in both the datasets
comparing fibroblasts from control to HGPS (dataset 2) and
comparing fibroblasts from control to HGPS treated with FTI
(dataset 3). Hence, abnormal expression of 288 of the 352 genes in
fibroblasts from subjects with HGPS was normalized after FTI-
treatment.
In addition, an additional t-test analysis was done directly
comparing fibroblasts from control individuals treated with FTI to
fibroblasts from subjects with HGPS treated with FTI. This
analysis indicated that only 1 gene PIK3CB (+2.166) was altered in
FTI-treated HGPS cells (Fig 4E). PIK3CB is a phosphoinoitide-3-
kinase that is functionally associated to apoptosis, survival,
migration, proliferation, cell cycle and adhesion. The IPA analysis
links PIK3CB with one network associated to lipid metabolism.
Therefore, the difference in expression of only one gene indicated
that 99% of the genes in FTI-treated cells from subjects with
HGPS were expressed at the same levels as in FTI-treated normal
fibroblasts.
Validation of the microarray analyses by real-time RT-PCR
Differential expression of selected genes found to be significantly
different in the microarray analyses was confirmed by real-time
RT-PCR. To compare fibroblasts from subjects with HGPS to
unaffected controls, we selected genes identified in the microarray
analysis that were upstream regulators in the signaling pathway.
For normal fibroblasts with and without FTI treatment, we
selected genes that were upstream regulators in the signaling
network. For fibroblasts from subjects with HGPS with and
without FTI treatment, we selected genes that showed the greatest
fold changes in expression. We also measured the expression of
PIK3CB in FTI-treated fibroblasts from subjects with HGPS and
unaffected controls, as this was the only gene identified by
microarray analyses to be differentially expressed between these
experimental groups. In all cases, gene expression differences
measured by real-time RT-PCR were consistent with those
measured in the microarray analyses (Fig. 5A, B, C and Figure S6).
Potential relationship between gene expression
alterations in HGPS and physiological aging
Our results implicate a defective lamin A-Rb signaling network
as a pathogenic mechanism in HGPS, a disease with features of
premature aging. We investigated whether alterations in this same
signaling network might occur during physiological aging. We
screened mRNA extracted from human skin biopsies from
individuals 38 to 90 years of age. The skin samples were derived
from an already established skin biopsy tissue bank (approved by
the Columbia University Medical Center Institutional Review
Board), which has been described previously [31]. Total mRNA
extractions from human skin samples were performed as described
previously [31]. Remarkably, lamin A/C transcripts were
increased in skin from individuals 87 to 90 years old (Fig. 5D).
In contrast, Rb mRNA was already decreased in skin from 70 to
72-year-old subjects (Fig. 5D), indicating that changes in LMNA
and RB1 expression occur during physiological aging. Further-
more, Western blot analyses of proteins extracted from skin
showed that A-type lamins were increased in samples from middle
aged and elderly individuals (Fig. 6A, B). Low levels of progerin
were also detected by indirect immunofluorescence microscopy
using a specific antibody in a restricted number of dermal
fibroblasts in skin sections derived from elderly subjects (Fig. 6C).
However, progerin expression was too low to detect by Western
blot analyses of proteins extracted from skin as previously reported
[31]. Rb, which is expressed at low levels in normal skin, was
Figure 1. Genome-wide expression profiling of HGPS and control fibroblast cultures. (A) Microarray plot profiles indicate changes in gene
expression in control, HGPS, FTI-treated control and FTI-treated HGPS fibroblasts. Each continuous line corresponds to the normalized intensity value of an
individual probe set. Line colors denote the intensity of the signal (red: strong and blue: low signal). Probes that satisfied a greater or less than two-fold
cutoff and statistically significant difference of p,0.01 are displayed. (B) Pie chart indicates the predicted subcellular localization of proteins encoded by
the 352 genes differentially expressed in HGPS. The list of differentially expressed genes in HGPS versus control cells was analyzed using Ingenuity
Pathway Analysis (IPA) and encoded proteins assigned a subcellular localization based on information contained in the Ingenuity Knowledge Base. (C)
Genes differently expressed in HGPS (352 genes) were assigned to diverse cellular functions using the ‘‘Functional Analysis’’ tool of IPA software (www.
ingenuity.com). Columns represent groups of genes associated with specific cellular functions (x-axis). The significant genes were compared to IPA
database and ranked according to a p-values generated with Fisher extract test. P-values less than 0.05 indicates a statistically significant, non-random
association between a set of significant genes and a set of all genes related to a given function in IPA database. The ratio (y-axis) represents the number of
genes from the dataset that map to the pathway divided by the number of all known genes ascribed to the pathway. The yellow line represents the
threshold of p,0.05. (D) As described above, the 352 genes were assigned to diverse physiological systems according to IPA.
doi:10.1371/journal.pone.0011132.g001
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weakly detected using immunofluorescence microscopy in samples
from young individuals and barely detected in samples from older
subjects (Fig. 6A left panel). These findings indicate that lamin A
and Rb levels change during physiological aging and suggest that
defects in a lamin A-Rb signaling pathway might occur similarly to
what we have identified in cells from subjects with HGPS.
Discussion
Inhibition of protein farnesyltransferase activity by FTIs has
been shown to improve abnormalities in nuclear morphology in
cells from subjects with HGPS and from animal models of the
disease [15,16,17,18,19,20,32]. FTIs also improve the progeria-
like phenotypes of mouse models of HGPS [22,23]. Presumably,
blocking farnesylation of progerin, the truncated prelamin A
expressed as a result of the G608G LMNA mutation which is
responsible for most cases of HGPS, renders it less toxic. However,
the molecular mechanisms by which progerin exerts its toxicity
and whether FTI treatment reverses specific molecular defects
induced by progerin remain largely unknown. We have now
identified a defective lamin A-Rb signaling network in cells from
subjects with HGPS and demonstrated that treatment of cells with
an FTI reverses abnormalities in the expression of genes encoding
proteins in this network.
We compared our gene expression profiles to those of previous
studies that have examined gene expression in HGPS and found
very little overlap (3.5% overlap of differentially expressed genes
with Scaffidi and Mitseli [28] and less than 1% with Csoka et al.
[27] (Table S1). Csoka et al.[27] used fibroblasts from only three
subjects ages 8 to 14 years of age whereas we used cultured
fibroblasts from five subjects with HGPS obtained at earlier ages
(age 1 to 4 years). As the growth rate and proliferation potency of
fibroblasts from subjects with HGPS decrease with cellular age in
vitro and the donor’s age, this could partially explain the differences
between our results. Importantly, the average age of death in
HGPS is 12–15 years, which suggests that the cellular phenotype
may be severely altered in older children [4]. Scaffidi and Misteli
[28] generated immortalized normal fibroblasts that overexpressed
progerin and examined gene expression in only two lines, making
a comparison difficult given the very different system and the low
statistical power from using only two biological replicates.
Separately, Fong et al. [33] used RT-PCR to examine expression
of several genes selected from these previous studies in normal
fibroblasts transfected with antisense oligonucleotides that increase
LMNA alternative RNA splicing to generate progerin. We found
that four of seven genes they tested were similarly differentially
expressed in the fibroblasts we used from subjects with HGPS
(Table S2). An earlier study by Ly et al. [25] used fibroblasts from
three donors with HGPS of age 8 to 9 years and found 61 genes
differently expressed in young subjects compared to old subjects
and with HGPS subjects. Of these 61 genes, 49 were differentially
expressed in HGPS versus young individuals [25]. Comparison of
these 49 genes against the 352 genes differentially expressed in
HGPS identified in our study indicated an overlap of 22 genes. An
additional study from Park et al [26] compared gene expression in
fibroblasts from only one subject with HGPS to that of cultured
fibroblasts in replicative senescence; no statistical criteria were
applied. Although HGPS is an extremely rare disease, to the best
of our knowledge we have used the most biological replicates so far
in any study of genome-wide gene expression in actual patient
material. We also validated our microarray data using information
from the literature, by screening databases and by performing RT-
PCR for selected genes. We confirmed by RT-PCR that Rb
mRNA levels were decreased in HGPS cells in comparison the
control cells. No change in Rb gene expression level was reported
in previous microarray analyses on HGPS cells or HGPS cell
models [26,27,28].
Most importantly, rather than providing a descriptive list of
genes with altered expression levels, our methods identified a novel
signaling network starting with the lamin A-Rb interaction that is
altered in HGPS.
The potential link between progerin and Rb in the orchestration
of cell cycle and proliferation defects was previously suggested by
studies demonstrating that lamin A and C interact with Rb
[30,34]. Rb is a tumor suppressor and major cell cycle regulator
that, in its hypophosphorylated state, binds to and inhibits the E2
factor (E2F) family of transcription factors required for cell cycle
progression [36]. Upon hyperphosphorylation of Rb by cyclin/
cyclin-dependent kinase complexes, E2F is released to initiate S
phase. A role for lamins in this process is further suggested by the
finding that hypophosphorylated Rb is tightly associated with
lamin A/C-enriched nucleoskeletal preparations of early G1 cells
[29]. In HGPS cells there is evidence for a significant reduction in
hyperphosphorylated Rb in HGPS fibroblasts (Dechat et al. 2007).
In our experiments, we found a decreased level of Rb expression at
the mRNA and protein levels in HGPS (see Figure 2 and Figure 6).
Previously, a small fraction of lamin A/C was shown to
colocalize with Rb and E2F1 in nuclear foci during G1-phase [37].
In HGPS cells, we could not detect lamin A foci. Whether Rb foci
remain associated with E2F1 remains to be further investigated. In
HGPS cells, our microarray analysis indicated a decrease in Rb
levels without changes in E2F1 levels. We further investigated
whether E2F1 levels might be altered by indirect immunofluores-
cence microscope and observed no changes in the nuclear intensity
of the E2F1 signal between HGPS and normal fibroblast cells
(data not shown). Previously, the localization of Rb and E2F1 in
cells from Lmna2/2 mice indicated that while Rb levels were
reduced, a portion of Rb remained localized to nuclear foci but
displayed reduced overlap with the E2F1 signal [35]. The
expression levels of E2F1 in Lmna2/2 cells in comparison to wild
type cells has not yet been reported. However, the lack of
association between Rb and E2F1 in nuclear foci in the absence of
lamin A/C could indicate an alteration in Rb control of E2F1
Figure 2. The lamin A-Rb network. The main network (center left) shows downstream interactions between lamin A/C and the 352 differentially
expressed genes in HGPS fibroblasts. The network was built using MetaCore analyses, which finds known interactions between gene products. (A)
The network divides into several distinct regions, the main region being the regulatory and signaling network. (B) The detailed view of the main
region (top right) shows that the only gene differentially expressed in HGPS directly downstream of lamin A/C (layer 1) is that encoding Rb (layer 2). In
turn, most of the immediate downstream partners of Rb included in this dataset are p107, NCOA2, SP1, and ATF-2 and E2F1 (layer 3). Of the
remaining genes that occur downstream of layer 3, nearly half of the 280 genes interact with only one or more of these transfactors associated to the
main network (center left); these gene products are placed above the centre. From layer 4 and 5, most of the genes can be connected at least to one
entity according to GeneGO. In the HGPS dataset, 124 genes that had no known interactions in GeneGO are not shown. From the center regulatory
and signaling network (zoom left, panel B)), several groups of genes segregate into six subnetworks, based on mutual interactions: a group denoted
DNA repair (bottom left, panel (C)), motility (bottom right, panel (D)), and three circles of genes regulated by E2F1, ATF-2 and SP1, respectively.
Symbols associating the genes with functions are indicated. Genes labeled with blue circles were downregulated and red circles were upregulated.
Higher magnifications of panels A to D are provided in Figures S1, S2, S3 and S4.
doi:10.1371/journal.pone.0011132.g002
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activity [35]. Further studies will be needed to understand how
expression levels of lamin A/C, Rb, and E2F1 might affect each
other’s expression levels, interactions and subnuclear localization.
In addition to its role in cell cycle control, Rb also regulates
cellular differentiation. In the absence of lamin A/C in muscle
cells derived from Lmna2/2 mice, reduced levels of Rb and other
transcription factors regulating muscle cell differentiation was
reported [38]. This study provide an additional link between lamin
A/C-Rb and its potential role in muscle cell differentiation [38].
Immunohistochemical analysis of Rb distribution did not reveal
any obvious alteration besides a decreased Rb signal in some
nuclei of cells from subjects with HGPS (Figure S7). Rb was also
detected in the most dysmorphic nuclei exhibiting a strong
progerin staining, indicating the accumulation of high levels of
progerin protein (Figure S7) as reported previously [15]. Based on
these previous studies, decreased Rb expression or phosphoryla-
tion status in HGPS cells appears to be implicated in the
deregulation of proliferation. Whether the interaction of A-type
lamin with Rb is impaired in HGPS cells remains to be further
addressed. However, our present study together with previously
published observations support the potential implication of a
defective lamin A/C-Rb signaling network in the HGPS cellular
phenotype. In support of our finding, a similar potential link
between an altered Lamin A/C-Rb signaling was previously
reported in cells derived from Lmna2/2 mice model [35]. In cells
lacking lamin A/C the levels of Rb was decreased while its mRNA
Figure 3. FTI inhibition of prelamin A and progerin farnesylation and FTI-induced gene expression changes in fibroblasts from
normal subjects. (A) Western blot analysis of protein extracts of fibroblasts from individuals with HGPS and controls that were treated or untreated
with FTI (1.5 mM lonafarnib daily for three days). Blots were probed with anti-lamin A/C (LA/C), anti-prelamin A (preLA), anti-actin, and anti HDJ-2
antibodies. Increase in levels of prelamin A and non-farnesylated HDJ-2 with FTI treatment are indicated. (B) 65 genes were differentially expressed in
FTI-treated control cells. The signaling network was built upon functional association between protein farnesyltransferase (FTase), the enzymatic
activity of which is inhibited by FTI, lamin A/C and Rb even though expression of all three transcripts remained unchanged with FTI treatment. Of
note, lamin A is a known substrate for FTase. Downstream FTase interactions between all the 65 genes differentially expressed in FTI-treated control
cells have been incorporated based on their interactions according to MetaCore analysis. The MetaCore analysis identified two transfactors, E2F1 and
c-Myc, and one transfactor regulator, REP-1 that permit linking all those 65 genes into this single network. Symbols associating the genes functions
are indicated. Genes labeled with blue circles were downregulated and by red circles were upregulated.
doi:10.1371/journal.pone.0011132.g003
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Figure 4. Genome-wide expression profiling of FTI-treated and untreated fibroblasts from subjects with HGPS. (A) Venn diagram
comparison of microarray datasets of controls versus control-FTI, or HGPS and/or HGPS-FTI. 65 genes were differentially expressed in fibroblasts from
control subjects after FTI treatment compared to no treatment (Control+FTI; red); 352 in fibroblasts from subjects with HGPS compared to those from
control subjects (HGPS; green); and 804 in fibroblasts from subjects with HGPS after FTI treatment compared to untreated controls (HGPS+FTI; blue).
Genes with altered expression common between these different datasets are shown as areas of overlap with different colors in the Venn diagram
Defective Rb Signaling in HGPS
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level remained unchanged in comparison to wild type cells [35].
These findings suggested that the Rb was unstable in the absence
of lamin A/C. In HGPS cells, we observed a decrease in both
mRNA and protein levels of Rb. Our findings indicate that the
lamin A/C-Rb signaling might be altered differently depending on
the status of A-type lamins in cells (absence of A-type lamins
expression versus expression of an abnormal lamin A variant,
progerin). Further studies are required to understand the
molecular mechanisms driven by alterations in A-type lamins on
Rb signaling pathways.
FTI treatment of cells from subjects with HGPS leads to a
significant reversal of the abnormal expression of genes encoding
proteins in the lamin A-Rb signaling network. This is consistent with
the improved phenotypes that result from blocking protein
farnesylation in cellular and animal models of the disease
[16,17,18,20,21,23]. Defective Rb activity appeared to be respon-
sible for the repression of the large set of downstream transcription
factors and regulators. To evaluate the impact of FTIs, we also
investigated FTI-induced gene expression changes in fibroblasts
from unaffected controls. Remarkably, Rb appeared again in this
dataset as a key regulator of the downstream events. Not surprisingly,
FTI-treated cells from subjects with HGPS demonstrated a near
total reversal (99%) of abnormally expressed genes in comparison to
FTI-treated control cells. Our finding suggests that a potential
correction of the HGPS phenotype does not necessarily require a full
inhibition of protein farnesyltransferase but rather points to the
importance of normalizing Rb expression levels and function.
The results of our study further support the potential use of FTIs
as therapeutic agents in HGPS. A phase II clinical trial treating
children with HGPS with lonafarnib, the FTI we used in this
study, was initiated in spring of 2007 [39]. Because of known
toxicity, the dose of lonafarnib administrated to these children may
generate tissue concentrations below those necessary to obtain the
effects we observed in vitro. Therefore, in human subjects, other
drugs in addition to an FTI may be necessary to inhibit protein
prenylation to a similar extent as in cultured cells. One possibility
is to add a statin and an aminobisphosphonate, which have been
shown to inhibit prelamin A prenylation and improve the
phenotype of mice deficient in Zmpste24 [24]. Furthermore, our
findings suggest that screening candidate molecules against targets
we identified in the lamin A-Rb signaling network could identify
novel therapeutic approaches to treat HGPS. Proteins in this
network could also serve as biomarkers for HGPS.
Because the lamin A-Rb interaction is a new signaling axis in
the pathogenesis of HGPS, we investigated its potential role in
physiological aging. We found that LMNA and RB1 expression
appeared to be inversely modulated in the elderly. These
observations were similar to our findings in cells from subjects
with HGPS. Although lamin A and lamin C levels were not
altered, an abnormal prelamin A variant, progerin, is expressed
and Rb expression is decreased. In addition to changes in the
expression of A-type lamins, several studies suggest that abnormal
prelamin A may accumulate in normal aging [14,31,40,41]. Our
results, therefore, suggest that therapeutic approaches to re-
establish a proper lamin A-Rb signaling network may be beneficial
in preventing complications of physiological aging.
Materials and Methods
Cell culture and FTI treatment
Dermal fibroblasts from subjects with HGPS were obtained from
the Progeria Research Foundation (www.progeriaresearch.org).
The following fibroblasts were used: HGADFN003 (M, age 2),
HGADFN127 (F, age 3), HGADFN155 (F, age 1), HGADFN164
(F, age 4) and HGADFN188 (F, age 2). Age-matched control
dermal fibroblasts were obtained from Coriell Institute for Medical
Research (Camden, NJ). The following cell lines were used:
GM01652C (F, age 11), GM02036A (F, age 11), GM03349C
(M, age 10), GM03348E (M, age 10), GM08398A (M, age 8). The
Institutional Review Board at Columbia University Medical Center
approved the use of human cells established from skin biopsies from
patients with HGPS and unaffected individuals.
Cells were cultured in DMEM containing 15% fetal bovine
serum, 1% glutamine and 1% penicillin/streptomycin. Cells were
subcultured at 80% confluency to keep cultures in growth phase
and collected at population doublings between 22 and 27.
Treatment with the FTI lonafarnib (Schering-Plough, Kennil-
worth, NJ) was initiated when the cells reached 45–50%
confluency. Lonafarnib was added to the culture media to a
concentration of 1.5 mM FTI daily for three days. Untreated
fibroblasts were cultured in parallel with added vehicle (DMSO).
Cellular toxicity was determined by Trypan blue exclusion.
Preliminary studies were conducted with varying lonafarnib
concentrations and 1.5 mM was selected, as higher concentrations
caused increased cell death and lower concentrations less
effectively blocked protein farnesylation (data not shown).
RNA Preparation
Total RNA was extracted from the cell pellets using the Rnase
Mini kit (Qiagen, Valencia, CA). Spectrophotometric quantifica-
tion of RNA was performed and the purity assessed by
measurement of the 260 nm/280 nm absorbance ratio. Ratios
between 1.9 to 2.1 were accepted. Additionally, samples were run
on a 1.2% agarose gel to examine integrity of the RNA. All gels
showed two discrete bands at the 4.5 kb and 1.9 kb, representing
the 28S and 18S ribosomal subunits, respectively (data not shown).
Microarray processing
RNA samples were amplified once using the One Cycle Target
Labeling and Control Reagents and labeled for hybridization
using the Affymetrix reagents and protocols (Affymetrix, Santa
Clara, CA). Prior to hybridization, biotin-labeled cRNA samples
were examined on an Agilent 2100 Bioanalyzer (Agilent
Technoligies, Palo Alto, CA) to ensure quality. The samples were
hybridized to U133 Plus 2.0 Arrays (Affymetrix) at the Columbia
University Microarray Core Facility.
with numbers of common genes indicated. (B) Pie chart indicates the subcellular localization of the encoded proteins of the differentially expressed
genes between control and HGPS-FTI datasets according to information contained in the Ingenuity Knowledge Base. (C) Genes differentially
expressed between controls versus HGPS-FTI datasets were assigned to diverse cellular functions according to IPA and (D) were associated to
canonical pathways according to IPA. The significant genes were compared to IPA database and ranked according to p-values generated with Fisher
extract test. P-values less than 0.005 indicate a statistically significant, non-random association between a set of significant genes and a set of all
genes related to a given function in IPA database. The ratio (y-axis) represents the number of all known genes ascribed to the pathway. The Yellow
line represents the threshold of p,0.05. (E) Comparison of gene expression alterations between FTI-treated control cells (yellow) with FTI-treated
fibroblasts from subjects with HGPS (red). Using criteria of corrected p-value from unpaired t-test ,0.01 and two-fold change in expression, only one
gene, PIK3CB was upregulated in FTI treated cells from subjects with HGPS compared to cells from normal subjects treated with FTI. Therefore, 99% of
the genes in FTI-treated cells from subjects with HGPS were expressed at the same levels as in FTI-treated normal fibroblast.
doi:10.1371/journal.pone.0011132.g004
Defective Rb Signaling in HGPS
PLoS ONE | www.plosone.org 9 June 2010 | Volume 5 | Issue 6 | e11132
Defective Rb Signaling in HGPS
PLoS ONE | www.plosone.org 10 June 2010 | Volume 5 | Issue 6 | e11132
The microarray data have been deposited in the European
Bioinformatics Institute’s ArrayExpress (www.ebi.ac.uk/arrayexpress)
under accession number: E-MEXP-2597 along with detailed protocol
notes.
Microarray data analysis
Data outputs were normalized and analyzed using GeneSpring
GX 10.0 commercial software package (Agilent Technologies).
Affymetrix data were uploaded into GeneSpring GX, normalized
and quality control assessment was run to ensure the integrity of
the samples. A t-test comparison was performed for each
experimental group. The P-value cutoff was set to 0.01, a
Benjamini-Hochberg correction was applied and the significant
fold difference was considered two-fold above or below baseline.
For interpretation of the results, MetaCore and GeneGo (www.
Genego.com) and Ingenuity Pathways Analysis (Ingenuity Sys-
tems, www.ingenuity.com) software were used. Datasets contain-
ing gene identifiers and corresponding expression values were
uploaded in the applications. An up or down change of two-fold or
greater was set to identify genes whose expression was differentially
regulated. These genes, or focus molecules, were overlaid onto a
global molecular network developed from information contained
in the Ingenuity Pathways Knowledge Base.
Network Analysis and Visualization
Gene sets were analyzed using MetaCore (www.genego.com). We
built networks using as far as possible all and only genes belonging to
the differentially regulated sets. The assembly of the networks exhibited
in Fig. 2 and Fig. 3 were initially loaded with only the differentially
regulated genes from the respective datasets. Then we added the
known causal genes (encoding A-type lamins for Fig. 2 and protein
farnesyltransferase for Fig. 3) and manually laid out the remaining
genes in a semi-circular network based on the directness of the
downstream interactions to the causal gene. In both cases, only a small
number of genes had direct downstream interactions. For these and
subsequent layers, we applied two rules. Rule 1: if a gene was
downstream only to genes on the current layer or more inner layers,
and if the gene had no genes downstream of it, it was moved to the
outermost layer; otherwise, it was moved to the next layer. Rule 2: after
the second layer, if the gene did not have downstream connections to
genes in the current or previous layer, the gene was moved to a layer
beyond the current layer. Following the initial manual layout, a
number of differentially expressed genes were still not assigned to a
downstream position from the causal gene. We used the MetaCore
transfactor analysis tool to determine which transfactors could be
implicated based on published data. This tool produces a list of
transfactors belonging to the dataset analyzed. The list is ranked by an
estimate of likelihood of being involved. Starting with the most likely,
we added transfactors to the network, manually re-adjusting the
network each time. We moved down the list until we had either
exhausted the possible transfactors or finished the list of genes.
Real-time RT-PCR analysis
We synthesized cDNA using Omniscript Reverse Transcriptase
(Qiagen) using total cellular RNA as template. RNA from fibroblasts
from three subjects with HGPS and three controls, cultured with or
without FTI, was used. Primers were designed using Primer3 (http://
frodo.wi.mit.edu/cgi-bin/primer3/primer3_www.cgi). The list of
genes that were validated by RT-PCR and their corresponding
primers are shown in Table S3.
Real-time RT-PCR reactions contained Power SYBR Green
PCR mastermix (Applied Biosystems), 200 nM of each primer,
and 0.1 ml of template in a 20-ml reaction volume. Amplification
was carried out using the 7300 Real-Time PCR Detection System
(Applied Biosystems) with an initial denaturation at 95uC for two
minutes followed by 50 cycles at 95uC for 30 seconds and 62uC for
30 seconds. Three experiments were performed for each assay, in
which the samples were run in triplicate. GAPDH was used as an
endogenous control and quantification was performed using the
relative quantification method where the real-time PCR signal of
the experimental RNA was measured in relation to the signal of
the control. The 2(DDCT) method was used to calculate relative
changes in gene expression [42].
Western blot analysis
Cells were extracted in Laemmli sample buffer (Bio-Rad) and
heated for five minutes at 95uC. Approximatey 30 mg total protein
extracts were loaded in parallel on a 7.5% polyacrylamide gel. An
average of 7 mg of human skin tissues were extracted in Laemmli
buffer using the bullet blender according to manufacturer
instructions (Next Advance, Averill Park, NY). Approximately
40 mg skin protein extracts were loaded on the gel. After
separation by electrophoresis, proteins were transferred to
nitrocellulose membranes and incubated with blocking buffer as
described previously [12]. Membranes were incubated sequentially
with anti-prelamin A C20 antibodies (Santa Cruz Biotechnology,
Santa Cruz, CA), anti-lamin A/C antibodies [43] (kindly provided
by Dr. Nilabh Chaudhary), anti-actin antibodies (Sigma-Adrich,
St. Louis, MO) and anti-HDJ-2 (Abcam, Cambridge, MA),
washed and then incubated with a corresponding secondary
antibody coupled to horseradish peroxidase (Jackson ImmunoR-
esearch Laboratories, West Grove, PA). Other blots were similarly
incubated sequentially with anti-Rb (BD Biosciences Pharmingen,
San Diego, CA), anti- progerin [31], anti-lamin A (133A2, abcam),
anti-laminA/C and anti-actin antibodies. Proteins were visualized
using the enhanced chemiluminescence detection system (GE
Healthcare, Piscataway, NJ). Signals obtained on the autoradio-
grams were analyzed by densitometry using Quantity One 1-D
analysis software (Bio-Rad) on the scanned images.
Indirect immunofluorescence microscopy
Immunohistochemistry was performed on 6 mm frozen human
skin sections fixed in methanol/acetone (1V/1V) at 220uC for 10
minutes and washed in phosphate-buffered saline, then blocked in
phosphate-buffered saline containing 3% bovine serum albumin,
10% normal goat serum and 0.3% Triton X-100 for 30 minutes
and 1 hour in the same buffer without Triton X-100. Cells and
slides were incubated with anti-laminA/C and anti-Rb (BD
Biosciences Pharmingen), or anti-progerin and anti-Rb or anti-
lamin antibodies. The secondary antibodies were affinity purified
Figure 5. Real-time RT-PCR validation of microarray results for selected genes. (A) Validation of a set of genes identified in microarray
analysis comparing fibroblast from subjects with HGPS to controls. The mean value of expression for indicated genes measured using real time PCR
(red; p,0.05), and microarray (blue; p,0.01) are shown. (B) Validation of a set of genes identified in microarray analysis comparing fibroblasts from
control subjects with and without FTI treatment. (C) Validation of a set of genes identified in microarray analysis comparing fibroblasts from subjects
with HGPS with and without FTI treatment. (D) Relative expression of LMNA (L, red) and RB1 (R, blue) in human skin derived from 16 unaffected
individuals of various age groups was analyzed by quantitative real-time RT-PCR. A relative quantification method was used and the data from the 38
to 55-year-old age group were calibrated to a relative quantity of 1. All values were normalized to GAPDH (Materials and Methods).
doi:10.1371/journal.pone.0011132.g005
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Figure 6. Detection of lamin A/C and Rb in cells from subjects with HGPS and in normal human skin biopsies. (A) Left panel: Western
blot of proteins extracted from control fibroblasts (Control-1 [GM02036A], Control-2 [GM03349C]) and fibroblasts from subjects with HGPS
(HGADFN127, HGADFN155, HGADFN164, HGADFN188) sequentially probed with anti-lamin A/C, anti- lamin A, anti-progerin (progerin) and anti-actin
antibodies. Right panel: Western blot of protein extracts from skin of individuals at different ages as indicated (49 to 88 Year old, Y denote year). Blots
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Alexa Fluor 488 goat or donkey immunoglobulin G antibodies
(Life Technologies, Carlsbad, CA) and Cy3-conjugated IgG
antibodies (Jackson ImmunoResearch laboratories). All samples
were also counterstained with 49,6-diamidino-2-phenylindole
(Sigma-Aldrich). Images were acquired on an Axioplan fluores-
cence microscope (Carl Zeiss, Thornwood, NY).
Supporting Information
Figure S1 High magnification of Fig. 2, panel A.
Found at: doi:10.1371/journal.pone.0011132.s001 (1.37 MB TIF)
Figure S2 High magnification of Fig. 2, panel B.
Found at: doi:10.1371/journal.pone.0011132.s002 (3.89 MB TIF)
Figure S3 High magnification Fig. 2, panel C.
Found at: doi:10.1371/journal.pone.0011132.s003 (1.40 MB TIF)
Figure S4 High magnification Fig. 2, panel D.
Found at: doi:10.1371/journal.pone.0011132.s004 (1.63 MB TIF)
Figure S5 Genome-wide expression profiling of FTI-treated and
untreated control fibroblast cultures. (A) Genes differentially expressed
in normal fibroblasts treated with FTI compared to untreated normal
fibroblasts were assigned to diverse cellular functions according to
IPA, and (B) were associated with canonical pathways according to
IPA. (C) Pie chart indicates the subcellular localization of the protein
products of the differentially expressed genes according to information
contained in the Ingenuity Knowledge Base.
Found at: doi:10.1371/journal.pone.0011132.s005 (0.37 MB TIF)
Figure S6 Validation of the microarray analysis by real-time
RT-PCR. (A) Validation of a set of genes identified in microarray
analysis comparing fibroblasts from subjects with HGPS to
control. The mean value of expression for indicated genes
measured using real time RT-PCR are indicated (SD: standard
deviation; p,0.05), and microarray fold change (p,0.01) are
shown. (B) Validation of a set of genes identified in microarray
analysis comparing fibroblasts from control subjects with and
without FTI treatment. (C) Validation of a set of genes identified in
microarray analysis comparing fibroblasts from subjects with
HGPS treated with FTI to untreated fibroblasts from control
subjects. (D) Validation of the only gene differentially expressed
between FTI-treated fibroblasts from subjects with HGPS to FTI-
treated fibroblasts from control subjects. Fold changes measured
by real-time RT-PCR and microarray analyses are indicated.
Found at: doi:10.1371/journal.pone.0011132.s006 (0.71 MB TIF)
Figure S7 Distribution of progerin and Rb in cells from a subject
with HGPS. Immunohistochemy was performed on fibroblasts from
an unaffected control (GM03348) and a subject with HGPS
(HGADFN003) at PPD 25 to 30. Cells were stained with anti-
progerin antibody [31] (red) and anti-Rb monoclonal antibody (BD
Biosciences Pharmingen) (green). Chromatin was stained with dapi.
The triple merged signals are indicated. Scale bar, 20 mM.
Found at: doi:10.1371/journal.pone.0011132.s007 (1.31 MB TIF)
Table S1 Comparison of the differentially expressed genes in
fibroblasts from subjects with HGPS from this study to the
differentially expressed genes lists in studies by Scaffidi and Mitseli
[28] and Csoka et al.[27] Control versus HGPS differentially
expressed genes established after a statistical analysis using the t
test with 1% significance and 2-fold cutoff were compared to the
initial microarray analyses performed on three HGPS fibroblast
strains (Coriell cell repositories) derived from patients at age 8
(AG11513), 9 (AG10750) and 14 years old (AG11498)[27]. This
small overlap may be due to variation intrinsic to each cell, in
addition to the fact that cells from subjects with HGPS exhibit
increased variation in cellular phenotype with cellular age in vitro
and with the donor’s age. Our study was performed using five
fibroblast cultures from five subjects with HGPS at age 2 to 4 years
old, kindly provided by Progeria Research Foundation. Cells were
collected at an early PPD (,25) when their growth rate remained
similar to that of control fibroblast cultures. Phenotypic variations
and different levels of progerin expression can contribute to the
heterogeneity between fibroblasts from subjects with HGPS. We
compared the control versus HGPS gene list with another study
from Scaffidi and Mitseli that used a cellular model for HGPS by
overexpressing progerin in normal immortalized fibroblasts [28]
and found very little overlap.
Found at: doi:10.1371/journal.pone.0011132.s008 (0.07 MB TIF)
Table S2 Screening of a set of genes that were previously suggested
to be perturbed in HGPS cells [28,33]. Using the same olignucleo-
tides for RT-PCR described by Fong et al 2009[2], we screened
cultured fibroblasts from subjects with HGPS and from control
individuals used in this study. The fold change between fibroblasts
from subjects with HGPS and from control individuals in mRNA
transcript for the corresponding genes are indicated with a P,0.05.
Found at: doi:10.1371/journal.pone.0011132.s009 (0.09 MB TIF)
Table S3 List of primers used for real time PCR.
Found at: doi:10.1371/journal.pone.0011132.s010 (21.31 MB
TIF)
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